Life Technologies Corporation sequence-based system for HLA typing

Thursday, 21 February, 2013 | Supplied by: Life Technologies


Life Technologies Corporation has received US Food and Drug Administration (FDA) 510(k) clearance for its 3500 Dx Genetic Analyzers and SeCore HLA typing kits. The Applied Biosystems 3500 Dx/3500xL Dx CS2 Genetic Analyzers, Invitrogen SeCore HLA Sequencing Kits and uTYPE Dx HLA Sequence Analysis Software constitute the first 510(k)-cleared, sequence-based system for HLA typing in the United States.

Tissue typing is an essential component of determining compatibility between donors and patients for organ and bone marrow transplantation. HLA typing on the 3500 Dx offers labs an optimised, streamlined workflow said to have higher resolution than other molecular HLA typing technologies such as sequence-specific oligonucleotide (SSO) methods.

Online: www.invitrogen.com
Phone: 1800 331 627
Related Products

Beckman Coulter Life Sciences Basophil Activation Test (BAT) for food allergy research

Beckman Coulter Life Sciences introduces its next-generation Basophil Activation Test (BAT) to...

TopoGEN Topoisomerase Assay Kits

TopoGEN provides innovative reagents and kits for topoisomerase research and mechanism-based drug...

Alamar Biosciences NULISAseq Mouse Panel 120 for protein biomarker analysis

The multiplex panel encompasses a wide selection of proteins essential for studying key...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd